Skip to main content
Conference Coverage

Prescription Denials Associated With Treatment Abandonment and Increased Hospitalizations

Edited by 

Key Takeaways

  • A retrospective US study found that 14.1% of more than 106 million patients experienced a pharmacy claim denial in 2024, with semaglutide, tirzepatide, and albuterol accounting for the largest shares of denied claims.
  • Overall, 44.2% of patients abandoned their initially denied therapy.
  • Treatment abandonment was associated with significantly higher subsequent hospitalization rates across several medication classes, including Bruton tyrosine kinase (BTK) inhibitors, disease-modifying antirheumatic drugs (DMARDs), and antipsychotics.

A retrospective analysis of US pharmacy claims found that nearly half of patients experiencing a formulary-related prescription denial abandoned treatment in 2024. Using electronic health record (EHR) data linked to claims, researchers identified significant associations between prescription abandonment and subsequent hospitalization, raising concerns about the potential clinical consequences of pharmacy benefit restrictions.

Study Methods and Findings

Researchers analyzed the Veradigm Network EHR database linked with Komodo claims to identify pharmacy denials and associated patient outcomes in 2024. Denials were defined using National Council for Prescription Drug Programs (NCPDP) rejection codes 70 (Product Not Covered) and 75 (Prior Authorization Required).

Among 106 031 055 patients, 14 945 951 (14.1%) had at least 1 pharmacy claim with a qualifying rejection code.

Semaglutide accounted for the largest proportion of denied claims (7.4%), followed by tirzepatide (5.5%) and albuterol (5.2%). Tetracycline prescribed for acne had the highest individual denial rate at 87.9%.

Patients experiencing denials were older than those without denials (mean age, 53.8 vs 48.3 years). They were also more likely to be female (61.3% vs 56.3%), non-Hispanic (63.0% vs 54.7%), and Medicare beneficiaries (37.7% vs 29.3%). All differences were statistically significant (P < .01).

Among patients with denials and at least 12 months of continuous enrollment, 44.2% abandoned the denied therapy.

Clinical Implications of Prescription Abandonment

Patients who abandoned treatment experienced significantly higher subsequent hospitalization rates than those who eventually obtained their initially denied medication across several therapeutic classes.

The largest reported difference occurred among patients prescribed BTK inhibitors, with hospitalization rates of 34.5% among those abandoning therapy compared with 25.6% among those receiving treatment.

Similar differences were observed for DMARDs (19.0% vs 12.9%) and antipsychotics (23.3% vs 19.7%). All reported comparisons were statistically significant (P < .01).

These findings highlight potential challenges for US payers and managed care organizations balancing utilization management, medication access, and clinical outcomes.

Although formulary restrictions are intended to reduce inappropriate prescribing and health care expenditures, the observed associations suggest that prescription denials and subsequent treatment abandonment may warrant additional consideration in pharmacy benefit design.

This retrospective analysis establishes associations rather than causation and does not determine whether the denials directly contributed to hospitalization.

Prioritizing Medication Access in Pharmacy Benefit Design

The study authors emphasized that formulary restrictions, while designed to control costs without compromising care, may have adverse downstream consequences for certain patient populations.

They concluded that patient-centered pharmacy benefit designs prioritizing medication access are important for addressing potential disparities in health care delivery and reducing avoidable clinical deterioration.

Balancing Formulary Restrictions With Patient Outcomes

Overall, the findings demonstrate the prevalence of pharmacy claim denials in the US and their association with treatment abandonment and subsequent hospitalization. The results underscore the importance of evaluating clinical outcomes alongside cost containment when developing formulary policies and utilization management strategies.

Reference

Tkacz J, Cheng J. Quantifying pharmacy claim denial rates, demographic disparities, and outcomes associated with prescription abandonment in the U.S. Poster presented at: AMCP Nexus 2026; October 26-29; San Diego, CA. Accessed October 26, 2026. https://amcpnexus.org/sites/default/files/2026-10/2026_October%20JMCP%20Poster%20Abstract_SupplementFINAL.pdf